Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICAR: IGIV for COVID-19 ARDS
NCT04350580Phase 3Completed
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) comparing Intervention - IGIV with Placebo (2 arms). Primary endpoint: Ventilator-free days at 28 days. Started Apr 2020; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04350580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350580.